NCT01747746

Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study

Anticoagulation With Rivaroxaban in Post Cardioversion Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Cook County Health · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.

Detailed description

Patient who are electrically cardioverted require 1 month of anticoagulation (blood thinner). Rivaroxaban a Xa-inhibitor has been shown to be non-inferior to Warfarin (Vit K antagonist) the current standard of care in many treatment areas. Rivaroxaban will be compared to Warfarin historical control group studying the safety and efficacy in electrically cardioverted patients.

Conditions

• Atrial Fibrillation
• Stroke
• Thrombo-embolism
• Bleeding

Interventions

Type	Name	Description
DRUG	Rivaroxaban	Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin
DRUG	Warfarin and Enoxaparin	Historical Control

Timeline

• Start date: 2012-10-01
• Primary completion: 2014-10-01
• Completion: 2014-10-01
• First posted: 2012-12-12
• Last updated: 2015-02-03

Locations

1 site across 1 country: United States